查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1943515

光免疫療法市場－全球產業規模、佔有率、趨勢、機會及預測（依治療領域、最終用戶、地區及競爭格局分類，2021-2031年）

Photoimmunotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Area, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球光免疫療法市場預計將從 2025 年的 19.9 億美元成長到 2031 年的 36.5 億美元，複合年成長率為 10.64%。

這種標靶腫瘤治療方法利用抗體-光敏劑偶聯物，在近紅外線光活化後，可誘導精準的細胞壞死。此領域的發展主要受固態腫瘤發生率上升以及臨床上對既能保護器官功能又能限制全身毒性的治療方法的需求所驅動。此外，大量需要有效控制局部疾病的患者族群也進一步強化了這項需求。例如，美國癌症協會報告稱，2024年美國將新增約58,450例頭頸癌病例，凸顯了此類治療方案的重要性。

市場概覽
預測期 2027-2031
市場規模：2025年 19.9億美元
市場規模：2031年 36.5億美元
複合年成長率：2026-2031年 10.64%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

然而，近紅外線光在生物組織中的穿透深度較淺是市場成長的主要障礙。這種物理限制使得其治療效果僅限於淺層腫瘤或可透過內視鏡觸及的腫瘤，難以在不進行侵入性手術的情況下應用於深部惡性腫瘤。因此，光療系統固有的技術複雜性仍然是一個核心挑戰，並可能阻礙其在更廣泛的癌症類型中的臨床應用。

市場促進因素

由於研發投入的增加和臨床管線的不斷拓展，光免疫療法正迅速從實驗階段邁向商業性化治療方法。資金對於維持後期臨床試驗至關重要，尤其是使用抗體-光吸收劑偶聯物的專有系統需要嚴格的監管檢驗。正如2024年3月題為「樂天醫療完成1.19億美元E輪資金籌措」的新聞稿中所強調的，樂天醫療籌集了1.19億美元，用於加速其Alluminox平台的全球III期臨床試驗。這筆巨額資金籌措直接推動公司實現其戰略目標，即擴大治療方法的適應症範圍，並在關鍵國際市場獲得監管部門的核准，從而證實了精準細胞標靶治療的商業性潛力。

同時，全球範圍內不可切除的頭頸癌發病率不斷上升，推動了市場發展，促使人們迫切需要能夠控制局部病變且避免根治性手術相關副作用的治療方法。在傳統治療方法難以保留器官功能的高發生率地區，此因素尤其重要。根據樂天醫療株式會社2024年1月發布的題為「樂天醫療在印度成功治療首例患者」的新聞稿，印度每年新增頭頸癌病例超過20萬例，這凸顯了該療法的關鍵目標患者群。在全球範圍內，巨大的疾病負擔也凸顯了開發新型固體癌療法的迫切性。世界衛生組織（WHO）2024年2月發布的報告《日益加重的全球癌症負擔》估計，2022年全球將新增2000萬例癌症病例，凸顯了標靶治療的巨大市場潛力，因為標靶治療能夠降低全身毒性。

市場挑戰

近紅外線光穿透深度較淺是限制全球光免疫療法市場擴張的一大阻礙因素。這項物理限制使得該療法主要局限於治療表淺或內視鏡可及的腫瘤，大大限制了效用。因此，除非與複雜的外科手術或介入治療相結合，否則該技術在治療常見內臟腫瘤方面面臨許多挑戰。這種對可近性的依賴限制了適用患者群體，並增加了臨床工作流程的複雜性，阻礙了醫療機構的廣泛採用，而這些醫療機構更傾向於選擇能夠治療多種腫瘤類型的通用治療方法。

這種限制的影響在治療難以用外部光源照射的內臟惡性腫瘤時尤為顯著。例如，美國癌症協會 (ACS) 估計，2024 年美國將新增 234,580 例肺癌和支氣管癌病例。將足夠的光能輸送到這些深層組織結構是一項挑戰，這降低了光免疫療法相對於全身性治療的競爭優勢。因此，相關人員在將該治療方法確立為主要內臟癌症適應症的一線標準治療方案方面面臨許多挑戰。

市場趨勢

一項重要的轉變是將光免疫療法與免疫查核點抑制劑合併應用，以增強全身性抗腫瘤免疫力。光免疫療法透過誘導免疫抗原性細胞死亡來增強腫瘤微環境的敏感性，進而提高PD-1/PD-L1抑制劑在治療難治性固態腫瘤的療效。近期數據證實了這種協同效應，證實了先前接受過標準治療的複發性頭頸部鱗狀細胞癌（HNSCC）患者的生存期有所改善。根據樂天醫療2025年9月發布的關於一項Ib/II期臨床試驗的新聞稿，ASP-1929聯合治療Pembrolizumab的中位總生存期（OS）達到25.6個月，顯著超過了此前單藥治療的基準。

同時，市場的一個顯著特徵是臨床開發舉措的全球策略擴張，旨在獲得早期採用市場以外其他地區的監管核准。開發商正積極擴大臨床實驗，納入多區域隊列，以滿足監管要求，並在歐洲和亞太地區獲取可靠的數據。這一趨勢在針對局部晚期癌症的後期試驗中尤為明顯，透過納入更廣泛的患者群體來加速商業化進程。例如，樂天醫療在2025年7月的新聞稿中宣布，已將其針對複發性頭頸部鱗狀細胞癌的全球3期臨床試驗擴大至412名患者，並在東歐新增了一個臨床試驗點，以加速患者招募和檢驗。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球光免疫療法市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依治療領域（頭頸癌、轉移性黑色素瘤、其他）
    • 按最終用戶（醫院/診所、門診護理中心、生技/製藥公司、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美光免疫療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲光免疫療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區光免疫療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲光免疫療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲光免疫療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球光免疫療法市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Rakuten Medical, Inc.
  • Shimadzu Corporation
  • Modulight Corporation
  • Steba Biotech Ltd.
  • Luzitin SA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 12819

The Global Photoimmunotherapy Market is projected to expand from USD 1.99 Billion in 2025 to USD 3.65 Billion by 2031, reflecting a compound annual growth rate of 10.64%. This targeted oncological approach employs an antibody-photosensitizer conjugate that, when activated by near-infrared light, triggers precise cell necrosis. Growth in this sector is primarily fueled by the rising incidence of solid tumors and the clinical necessity for therapies that maintain organ function while limiting systemic toxicity. The demand is further solidified by a significant patient base needing effective management for locoregional diseases; for instance, the American Cancer Society reported that approximately 58,450 individuals in the United States were diagnosed with head and neck cancers in 2024, emphasizing the critical need for such therapeutic options.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.99 Billion
Market Size 2031USD 3.65 Billion
CAGR 2026-203110.64%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Nevertheless, a major obstacle to market growth is the shallow penetration depth of near-infrared light into biological tissues. This physical limitation confines the therapy's effectiveness to tumors that are superficial or accessible via endoscopy, complicating its use for deep-seated malignancies absent invasive surgical measures. Consequently, the technical intricacies involved in light delivery systems persist as a core challenge, potentially impeding widespread clinical adoption across a broader range of cancer types.

Market Driver

Increased investment in research and development, alongside the broadening of clinical pipelines, is hastening the progression of photoimmunotherapy from experimental stages to commercially viable treatments. Financial support is essential for maintaining late-stage trials, especially for proprietary systems using antibody-photoabsorber conjugates that demand rigorous validation for regulatory authorities. As highlighted in a March 2024 press release titled "Rakuten Medical Closes $119 Million Series E Financing," Rakuten Medical raised $119 million to fast-track its global Phase 3 clinical trial of the Alluminox platform. This significant funding directly advances the strategic goal of widening the therapy's indications and securing regulatory clearance in major international markets, thereby confirming the commercial potential of precision cell-targeting therapies.

Concurrently, the market is propelled by the growing global prevalence of unresectable head and neck cancers, which necessitates interventions capable of managing locoregional disease without the adverse effects associated with radical surgery. This driver is especially critical in regions with high incidence rates where conventional treatments frequently fail to preserve organ function. According to Rakuten Medical's January 2024 press release, "Rakuten Medical Announces First Patient Treatment in India," over 200,000 new head and neck cancer cases are diagnosed annually in India, identifying a key demographic for this treatment. Globally, the urgent need for new solid tumor treatments is highlighted by the massive disease burden; the World Health Organization's February 2024 report, "Global Cancer Burden Growing," estimated 20 million new cancer cases worldwide in 2022, underscoring the vast market potential for targeted therapies offering reduced systemic toxicity.

Market Challenge

The shallow penetration capability of near-infrared light serves as a significant restraint on the expansion of the global photoimmunotherapy market. Because of this physical restriction, the therapy is largely limited to treating superficial or endoscopically reachable tumors, effectively reducing its utility for deep-seated malignancies. As a result, the technology encounters substantial obstacles in managing high-volume internal cancers unless paired with complex or invasive surgical procedures. This dependency on accessibility restricts the eligible patient pool and adds complexity to clinical workflows, which discourages widespread adoption among healthcare providers who prefer versatile treatment options for a wide array of oncology cases.

The consequences of this limitation become apparent when addressing internal malignancies that are challenging to target with external light sources. For instance, the American Cancer Society estimated that 234,580 new cases of lung and bronchus cancer were diagnosed in the United States in 2024. The challenge of delivering adequate light energy to these deep tissue structures diminishes the competitive edge of photoimmunotherapy compared to systemic treatments. Consequently, market stakeholders encounter difficulties in establishing this modality as a primary standard of care for major internal cancer indications.

Market Trends

A significant shift involves combining photoimmunotherapy with immune checkpoint inhibitors to boost systemic anti-tumor immunity. By triggering immunogenic cell death, photoimmunotherapy sensitizes the tumor microenvironment, which enhances the effectiveness of PD-1/PD-L1 inhibitors in treating refractory solid tumors. Recent data validates this synergy, showing improved survival rates in patients with recurrent head and neck squamous cell carcinoma (HNSCC) who had previously exhausted standard treatments. According to a September 2025 press release from Rakuten Medical regarding the publication of a Phase 1b/2 clinical study, the combination of ASP-1929 and pembrolizumab resulted in a median Overall Survival (OS) of 25.6 months, markedly exceeding historical benchmarks for monotherapy.

At the same time, the market is defined by the strategic global broadening of clinical development initiatives aimed at obtaining regulatory approvals in various regions outside of early adopter markets. Developers are actively expanding pivotal trials to encompass multi-regional cohorts, thereby ensuring robust data and satisfying regulatory demands in Europe and the Asia-Pacific region. This trend is illustrated by the increasing scope of late-stage studies for locoregional cancers, which are incorporating wider patient demographics to hasten commercial readiness; for example, Rakuten Medical announced in a July 2025 press release that it had expanded its global Phase 3 trial for recurrent HNSCC to enroll 412 patients, adding new clinical sites in Eastern Europe to accelerate recruitment and validation.

Key Market Players

  • Rakuten Medical, Inc.
  • Shimadzu Corporation
  • Modulight Corporation
  • Steba Biotech Ltd.
  • Luzitin SA

Report Scope

In this report, the Global Photoimmunotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Photoimmunotherapy Market, By Therapeutic Area

  • Head & Neck Cancer
  • Metastatic Melanoma
  • Others

Photoimmunotherapy Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Biotechnology & Pharmaceutical Companies
  • Others

Photoimmunotherapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Photoimmunotherapy Market.

Available Customizations:

Global Photoimmunotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Photoimmunotherapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Area (Head & Neck Cancer, Metastatic Melanoma, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Biotechnology & Pharmaceutical Companies, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Photoimmunotherapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Area
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Photoimmunotherapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Area
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Photoimmunotherapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Area
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Photoimmunotherapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Area
        • 6.3.3.2.2. By End User

7. Europe Photoimmunotherapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Area
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Photoimmunotherapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Area
        • 7.3.1.2.2. By End User
    • 7.3.2. France Photoimmunotherapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Area
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Photoimmunotherapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Area
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Photoimmunotherapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Area
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Photoimmunotherapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Area
        • 7.3.5.2.2. By End User

8. Asia Pacific Photoimmunotherapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Area
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Photoimmunotherapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Area
        • 8.3.1.2.2. By End User
    • 8.3.2. India Photoimmunotherapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Area
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Photoimmunotherapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Area
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Photoimmunotherapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutic Area
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Photoimmunotherapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutic Area
        • 8.3.5.2.2. By End User

9. Middle East & Africa Photoimmunotherapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Area
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Photoimmunotherapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Area
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Photoimmunotherapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Area
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Photoimmunotherapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Area
        • 9.3.3.2.2. By End User

10. South America Photoimmunotherapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Area
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Photoimmunotherapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Area
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Photoimmunotherapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Area
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Photoimmunotherapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Area
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Photoimmunotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Rakuten Medical, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Shimadzu Corporation
  • 15.3. Modulight Corporation
  • 15.4. Steba Biotech Ltd.
  • 15.5. Luzitin SA

16. Strategic Recommendations

17. About Us & Disclaimer